Itching
Conditions
Brief summary
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in people with atopic dermatitis.
Detailed description
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the interleukin-13 is involved in inflammation and itch in atopic dermatitis by increasing the neuronal sensitivity to pruritogens. However, the physiological mechanisms by which IL-13 increases the itch sensitivity are unclear. The aim of this project is to use, for the first time in humans, the monoclonal antibody Lebrikizumab that inhibits IL-13 with high affinity as a novel experimental tool to modulate the IL-13 pathway and evaluate its role in the transmission and processing of itch and pain.
Interventions
A small drop of histamine dihydrochloride (1%, in saline) will be applied to two previously determined areas followed by a prick through the drop.
OTHERCowhage
Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin.
Sponsors
Aalborg University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Each participant will be treated with Lebrikizumab and will receive 2 pruritogens: Histamine and cowhage
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* 18-60 years • The patients should have an AD according to diagnosis by a board-certified dermatologist, with an Eczema Area and Severity Index (EASI), a validated scoring tool that grades the physical signs of AD of at least 7. The project team will be specifically trained and evaluated in the EASI assessment to ensure interindividual consistency.
Exclusion criteria
* Pregnancy or lactation * Drug addiction defined as any use of cannabis, opioids, or other drugs Moles, wounds, scars, or tattoos in the area to be treated or tested * Treatment within two weeks before start of the experiment with topical corticosteroids or calcineurin inhibitors. * Treatment within two weeks before start of the experiment with topical treatments (excluding emollients) on the skin areas selected for testing (eight weeks if treated with systemic treatments for AD such as methotrexate or azathioprine) * Treatment with antihistamines 72 hours before start of the experiment * Previous or current history of neurological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.) * Current use of medications that may affect the trial such as antihistamines and painkillers (use of antihistamines must be discontinued 72 hours before the experiment and all topical agents and emollients must be discontinued 24 hours before the experiment). * Use of systemic corticosteroids * Consumption of alcohol or painkillers 24 hours before the study days and between these * Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials) * Lack of ability to cooperate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measuring pain by computerized Visual Analog Scale Scoring | Day 3 | The subjects will be asked to rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates no pain and 100 indicates worst pain imaginable. |
| Average pruritis and pain numerical rating scale (NRS) | Day 1 | The subject will be asked to retrospectively rate the average and worst itch/pain on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain)experience they had during the last 7 days. |
| Skin peak pain numerical rating scale (SPP-NRS) | Day 1 | According to the SPP-NRS, the subject will be asked about worst skin pain they felt in the past 24 hours on an 11- point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain) |
| Peak pruritus numerical rating scale (PP-NRS) | Day 1 | The subject will be asked about the worst itch they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no itch and 10 = worst imaginable itch) |
| Eczema Area and Severity Index (EASI) | Day 1 | This scale is used for patients with AD to assess severity and extent of the disease. The investigator/physician will assign scores based on redness, scratching, thickness, lichenification and percentage of affected body regions |
| Dermatology Life Quality Index (DLQI) | Day 1 | This questionnaire is a simple 10-question validated questionnaire that measures the impact of the skin disease on several aspects of the patient's life over the past week. The DLQI sum score is calculated by summing up the score of each item. Questions are scored on a four-point Likert scale: 0, not at all/not relevant; 1, a little; 2, a lot; and 3, very much. |
| Itch Severity Scale (ISS) | Day 1 | This is a seven items questionnaire: itch description, frequency, effect on sleep, effect on mood, effect on sexual desire/function, itch intensity using Likert scale and body surface area involved |
| Patient Oriented Eczema Measure (POEM) | Day 1 | POEM is a questionnaire used for patients' self-monitoring of AD severity. It asks about the frequency of seven symptoms (itch, sleep disturbance, dryness, flaking, weeping, or oozing, bleeding, and cracking) in the past seven days, and the patient has to choose between these answers: No days, 1-2 days, 3-4 days, 5-6 days, Every day |
| Mechanically evoked itch (MEI) | Day 1 | MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). |
| Measuring itch by computerized Visual Analog Scale Scoring | Day 1 | The subjects will be asked to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates no itch and 100 indicates worst itch imaginable. |
| Superficial blood perfusion | Day 1 | Superficial blood perfusion (SBP) is measured by a Speckle contrast imager |
| Wheal reaction | Day 1 | Wheal reaction measurement will be conducted immediately after the removal of pruritogens by measuring the longest diameter with a ruler. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mechanical Pain Sensitivity (MPS) | Day 1 | This test is conducted with the same pinprick set used to test the MPT. |
| Pressure Pain Thresholds (PPT) | Day 1 | Pressure will be applied by a handheld electronic pressure algometer (Somedic AB, Stockholm, Sweden) on to the supinator muscle on the left forearm. |
| Cold Detection Thresholds (CDT) | Day 1 | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
| Warm Detection Thresholds (WDT) | Day 1 | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
| Cold Pain Thresholds (CPT) | Day 1 | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
| Pain to Supra-threshold Heat Stimuli (STHS) | Day 1 | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device |
| Heat Pain Thrteshold | Day 1 | — |
| Mechanical Pain Thresholds (MPT) | Day 1 | This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. |
Countries
Denmark
Outcome results
None listed